Overview

SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients

Status:
Withdrawn
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
A one-arm, single center phase 2 trial of SAbR plus ipilimumab plus nivolumab in advanced metastatic melanoma patients
Phase:
Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Treatments:
Antibodies, Monoclonal
Ipilimumab
Nivolumab